What is fluoxetine (Prozac) used for treating?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fluoxetine Treatment Indications

Fluoxetine is primarily indicated for the treatment of major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder as established by FDA approval. 1

FDA-Approved Indications

Major Depressive Disorder

  • Approved for adults and pediatric patients (children and adolescents)
  • Efficacy established in 5-6 week trials with adult and geriatric outpatients
  • Effective as maintenance therapy for up to 38 weeks following acute treatment 1

Obsessive-Compulsive Disorder (OCD)

  • Approved for both adults and pediatric patients
  • Effective dose range: 60-80 mg daily for optimal efficacy 2
  • Efficacy established in 13-week trials with OCD outpatients 1
  • Treats both obsessions and compulsions with a more favorable side-effect profile compared to older medications 3

Bulimia Nervosa

  • Approved for moderate to severe bulimia (at least 3 bulimic episodes per week for 6 months)
  • Effective at reducing binge-eating and vomiting behaviors
  • Standard therapeutic dose: 60 mg/day 1
  • Maintenance efficacy demonstrated for up to 52 weeks 1

Panic Disorder

  • Approved for treatment with or without agoraphobia
  • Efficacy established in 12-week clinical trials 1
  • Lower starting doses (5 mg) may be beneficial for panic disorder patients who cannot tolerate standard 20 mg dosing 4

Other Clinical Applications (Off-Label Uses)

  • Anxiety disorders: Effective for treating anxiety symptoms associated with depression 5
  • Pain management: Used in certain pain conditions, particularly in patients with depression 6
  • Premenstrual syndrome: Some evidence for efficacy 6
  • Eating disorders: Effective for anorexia nervosa in addition to its approved use in bulimia 6

Pharmacological Considerations

  • Metabolized through CYP2D6, which can lead to potential drug interactions 2
  • Lower lethal potential in overdose compared to tricyclic antidepressants 2
  • Black box warning for increased risk of suicidality in children, adolescents, and young adults 2
  • FDA safety labeling indicates caution in patients with congenital long QT syndrome or history of QT prolongation 5

Dosing Considerations

  • Major depression: Standard dose is 20 mg daily
  • OCD: Higher doses (60-80 mg) typically required for optimal efficacy 2
  • Panic disorder: Consider starting at lower doses (5 mg) and gradually increasing to 20 mg, as patients with panic disorder may be more sensitive to side effects 4
  • CYP2D6 poor metabolizers: May require dose adjustment due to higher drug concentrations (3.9-11.5 fold higher AUC in poor metabolizers) 5

Important Clinical Pearls

  • Response may take several weeks to develop fully
  • Approximately 38% of patients may not respond during initial 6-12 weeks of treatment 2
  • Higher doses increase risk of adverse effects and may lead to treatment discontinuation 5
  • Fluoxetine has a long half-life, which reduces withdrawal symptoms upon discontinuation compared to other antidepressants 3
  • Contraindicated in bipolar patients unless used with mood stabilizers, as it may trigger manic episodes 2

When prescribing fluoxetine, carefully consider the specific indication, appropriate dosing based on the condition being treated, and patient-specific factors such as CYP2D6 metabolizer status to maximize efficacy while minimizing adverse effects.

References

Guideline

Treatment of Mental Health Disorders with Fluoxetine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Use of low-dose fluoxetine in major depression and panic disorder.

The Journal of clinical psychiatry, 1993

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.